ArticleBioresources and bioprocessing2026
ATP regeneration-driven biocatalytic production of 1,12-dodecanediol with improved cofactor supply.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
1,12-Dodecanediol is a high-value chemical widely used in the polymer and fine chemical industries. However, its industrial production is currently based on petroleum-derived processes associated with high energy consumption and environmental concerns. To address these limitations, microbial bioconversion of 1,12-dodecanedioic acid (C12 diacid) to 1,12-dodecanediol (C12 diol) has been investigated as a sustainable production route. In this pathway, carboxylic acid reductase (CAR) requires ATP and NADPH as essential cofactors, making efficient cofactor supply an important factor for achieving high conversion efficiency. In this study, a recombinant Escherichia coli-based biocatalytic system was developed to enhance C12 diol production through ATP regeneration. ATP availability was identified as an important factor for whole-cell bioconversion, and a polyphosphate kinase 2 (PPK2) from Erysipelotrichaceae bacterium was introduced to regenerate ATP from AMP, increasing the conversion yield from 22.0% to 31.8% at 40 mM substrate. Supplementation with sodium hexametaphosphate (SHMP, polyP
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.